ny psc dsip NYS Department of Public Service (@nysdps) • Threads, Say more NYS Department of Public Service

Check product instructions

Loren Pickart estimated toxic action starting at approximately 22,500 mg (300-fold above effective doses), though some users report mild blood pressure effects even at normal doses

CagriSema's Advantages: First to Market: 6-12 month head start Leverages Wegovy Success: Built-in brand recognition Proven Semaglutide Component: Half the drug is already approved Strong Diabetes Data: Positions for dual indication No Dysesthesia: Cleaner safety profile in one key area Retatrutide's Advantages: Higher Efficacy: 28.7% vs 20.4% (8.3 points more) Superior BP Reduction: -14 mmHg vs likely similar to semaglutide Single Molecule: Potentially easier manufacturing Multiple Indications: OA, OSA, obesity, diabetes trials Novel Class: First triple agonist = strong IP protection The Verdict: Market Will Support Both These medications won't compete head-to-head

Velafermin (rhFGF-20) reduces the severity and duration of hamster cheek pouch mucositis induced by fractionated radiation

How does GHK-Cu affect the hair follicle